SCHEMBL7529037

SCHEMBL7529037

CC(=O)N(c1ccc(C(=O)O)cc1)c1ccc(C(=O)Nc2ccc(C=Cc3ccccc3)c(C(=O)O)c2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SNCA P37840 3/20 0.43
NR1H4 Q96RI1 2/20 0.43
NPC1 O15118 4/20 0.43
RAB9A P51151 4/20 0.43
KCNK3 O14649 1/20 0.43
KMT2A Q03164 5/20 0.42
PKM P14618 2/20 0.42
ITGB3 P05106 1/20 0.42
ITGAV P06756 1/20 0.42
ITGA2B P08514 1/20 0.42
FFAR1 O14842 1/20 0.41
PTPN1 P18031 1/20 0.41
ALDH1A1 P00352 1/20 0.41
POLB P06746 1/20 0.40
MEN1 O00255 2/20 0.40
CACNA1B Q00975 1/20 0.40
APBA1 Q02410 1/20 0.40
PPARG P37231 1/20 0.39
PPARA Q07869 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7529027 1.00 SNCA (0.43) SNCANR1H4NPC1RAB9AKCNK3
SCHEMBL7528779 0.93 PTPN1 (0.46) SNCANR1H4NPC1RAB9AKCNK3
SCHEMBL7528772 0.93 PTPN1 (0.46) SNCANR1H4NPC1RAB9AKCNK3
SCHEMBL7529029 0.88 SNCA (0.46) SNCANR1H4NPC1RAB9AKCNK3
SCHEMBL7528955 0.84 KMT2A (0.57) SNCANR1H4NPC1RAB9AKCNK3
SCHEMBL7528948 0.84 KMT2A (0.57) SNCANR1H4NPC1RAB9AKCNK3
SCHEMBL7528666 0.81 SNCA (0.47) SNCAKMT2APKMPTPN1ALDH1A1
SCHEMBL7528656 0.81 SNCA (0.47) SNCAKMT2APKMPTPN1ALDH1A1
SCHEMBL7528775 0.81 PTPN1 (0.46) SNCANR1H4NPC1RAB9AKCNK3
SCHEMBL7526004 0.79 ALDH1A1 (0.52) NPC1RAB9AKMT2APKMFFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020032218-A1 Substituted stilbenes as glucose uptake enhancers TELIK, INC. 2002-03-14 US claimed
US-6479548-B2 P-(BENZOYLAMINO)STILBENE DERIVATIVES TELIK, INC. 2002-11-12 US disclosed
US-20020032218-A1 Substituted stilbenes as glucose uptake enhancers TELIK, INC. 2002-03-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020032218-A1 Substituted stilbenes as glucose uptake enhancers SLC2A1, SLC2A8, SLC2A2 SNCA 3814/4885NR1H4 856/4885NPC1 428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.